The case for CAR T-cell therapy in follicular lymphomas
- PMID: 31416814
- DOI: 10.1182/blood.2019001843
The case for CAR T-cell therapy in follicular lymphomas
Conflict of interest statement
Conflict-of-interest disclosure: M.R.B. is a consultant and has received honoraria and research support from Novartis, Kite/Gilead, Juno Therapeutics, Celgene, and CRISPR Therapeutics.
Comment on
-
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.Blood. 2019 Aug 15;134(7):636-640. doi: 10.1182/blood.2019000905. Blood. 2019. PMID: 31648294 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources